Cel Sci Corporation (CVM)

[goodplenty100]

BioMed reports


Shares of CEL-SCI Corporation (NYSEMKT:CVM) were recently hit for no logical reason, but they have started to bounce back nicely this week, after an analyst initiated coverage on the "under a buck" stock with a $10 price target.

Technically speaking the stock looks primed to run to at least $1 today as the technicals are all lining up (see the chart below. Any bit of good news and shares could go even higher and we are anticipating their monthly update on patient enrollment, which is suddenly very active in 17 countries on 3 continents.

The stock valuation had suffered due to slow enrollment, but the numbers keep improving month after month. A positive news announcement in the next few days could be the perfect catalyst to add fuel here.

As you may know, CEL-SCI is in the middle of the world's largest Phase III trial for the treatment of head and neck cancer, a $6 Billion market. If CVM's drug Multikine(R) (Leukocyte Interleukin, Injection) proves to be effective, it would become a new way to treat head and neck cancer, by using the body's own immune defense system.The company's shares are way undervalued at this point, so this is a relatively low risk trade which can yield some quick profits.